• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血管加压素与V受体结合时的构象选择

Conformational selection of vasopressin upon V receptor binding.

作者信息

Che Kateryna, Muttenthaler Markus, Kurzbach Dennis

机构信息

University Vienna, Faculty of Chemistry, Institute of Biological Chemistry, Währinger Str. 38, A-1090 Vienna, Austria.

The University of Queensland, Institute for Molecular Bioscience, 306 Carmody Rd, 4072 St Lucia, Brisbane, Queensland, Australia.

出版信息

Comput Struct Biotechnol J. 2021 Oct 18;19:5826-5833. doi: 10.1016/j.csbj.2021.10.024. eCollection 2021.

DOI:10.1016/j.csbj.2021.10.024
PMID:34765097
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8567363/
Abstract

The neuropeptide vasopressin (VP) and its three G protein-coupled receptors (VR, VR and VR) are of high interest in a wide array of drug discovery programs. VR is of particular importance due to its cardiovascular functions and diverse roles in the central nervous system. The structure-activity relationships underpinning ligand-receptor interactions remain however largely unclear, hindering rational drug design. This is not least due to the high structural flexibility of VP in its free as well as receptor-bound states. In this work, we developed a novel approach to reveal features of conformational selectivity upon VP-VR complex formation. We employed virtual screening strategies to probe VP's conformational space for transiently adopted structures that favor binding to VR. To this end, we dissected the VP conformational space into three sub-ensembles, each containing distinct structural sets for VP's three-residue C-terminal tail. We validated the computational results with experimental nuclear magnetic resonance (NMR) data and docked each sub-ensemble to VR. We observed that the conformation of VP's three-residue tail significantly modulated the complex dissociation constants. Solvent-exposed and proline -configured VP tail conformations bound to the receptor with three-fold enhanced affinities compared to compacted or -configured conformations. The solvent-exposed and more flexible structures facilitated unique interaction patterns between VP and VR transmembrane helices 3, 4, and 6 which led to high binding energies. The presented "virtual conformational space screening" approach, integrated with NMR spectroscopy, thus enabled identification and characterization of a conformational selection-type complex formation mechanism that confers novel perspectives on targeting the VP-VR interactions at the level of the encounter complex - an aspect that opens novel research avenues for understanding the functionality of the evolutionary selected conformational properties of VP, as well as guidance for ligand design strategies to provide more potent and selective VP analogues.

摘要

神经肽血管加压素(VP)及其三种G蛋白偶联受体(VR1、VR2和VR3)在众多药物发现项目中备受关注。由于其心血管功能以及在中枢神经系统中的多种作用,VR1尤为重要。然而,支撑配体 - 受体相互作用的构效关系在很大程度上仍不明确,这阻碍了合理的药物设计。这尤其归因于VP在其游离状态以及与受体结合状态下具有高度的结构灵活性。在这项工作中,我们开发了一种新方法来揭示VP - VR1复合物形成时的构象选择性特征。我们采用虚拟筛选策略来探索VP的构象空间,以寻找有利于与VR1结合的瞬时采用结构。为此,我们将VP构象空间分解为三个子集合,每个子集合包含VP三残基C末端尾巴的不同结构集。我们用实验核磁共振(NMR)数据验证了计算结果,并将每个子集合对接至VR1。我们观察到VP三残基尾巴的构象显著调节了复合物的解离常数。与紧密或脯氨酸构型的构象相比,溶剂暴露且脯氨酸构型的VP尾巴构象与受体结合时亲和力提高了三倍。溶剂暴露且更灵活的结构促进了VP与VR1跨膜螺旋3、4和6之间独特的相互作用模式,从而导致高结合能。因此,所提出的“虚拟构象空间筛选”方法与NMR光谱相结合,能够识别和表征一种构象选择型复合物形成机制,该机制为在相遇复合物水平上靶向VP - VR1相互作用提供了新的视角——这一方面为理解VP进化选择的构象特性的功能开辟了新的研究途径,也为配体设计策略提供了指导,以提供更有效和选择性更强的VP类似物。

相似文献

1
Conformational selection of vasopressin upon V receptor binding.血管加压素与V受体结合时的构象选择
Comput Struct Biotechnol J. 2021 Oct 18;19:5826-5833. doi: 10.1016/j.csbj.2021.10.024. eCollection 2021.
2
Photoswitchable Probes of Oxytocin and Vasopressin.光致变色探针对催产素和血管升压素的研究
J Med Chem. 2023 Nov 9;66(21):14853-14865. doi: 10.1021/acs.jmedchem.3c01415. Epub 2023 Oct 19.
3
Molecular modeling of interactions of the non-peptide antagonist YM087 with the human vasopressin V1a, V2 receptors and with oxytocin receptors.非肽拮抗剂YM087与人血管加压素V1a、V2受体以及催产素受体相互作用的分子模拟
J Comput Aided Mol Des. 2001 Dec;15(12):1085-104. doi: 10.1023/a:1015905822671.
4
Identification of amino acid residues that direct differential ligand selectivity of mammalian and nonmammalian V1a type receptors for arginine vasopressin and vasotocin. Insights into molecular coevolution of V1a type receptors and their ligands.鉴定指导哺乳动物和非哺乳动物V1a型受体对精氨酸加压素和催产素产生不同配体选择性的氨基酸残基。深入了解V1a型受体及其配体的分子协同进化。
J Biol Chem. 2004 Dec 24;279(52):54445-53. doi: 10.1074/jbc.M408909200. Epub 2004 Oct 8.
5
Nature-inspired dimerization as a strategy to modulate neuropeptide pharmacology exemplified with vasopressin and oxytocin.受自然启发的二聚化作为一种调节神经肽药理学的策略,以加压素和催产素为例进行说明。
Chem Sci. 2021 Feb 4;12(11):4057-4062. doi: 10.1039/d0sc05501h.
6
Interactions of vasopressin and oxytocin receptors with vasopressin analogues substituted in position 2 with 3,3'-diphenylalanine--a molecular docking study.血管加压素和催产素受体与 2 位用 3,3'-二苯丙氨酸取代的血管加压素类似物的相互作用——分子对接研究。
J Pept Sci. 2013 Feb;19(2):118-26. doi: 10.1002/psc.2485. Epub 2013 Jan 10.
7
Heterodimerization of V1a and V2 vasopressin receptors determines the interaction with beta-arrestin and their trafficking patterns.血管升压素V1a和V2受体的异源二聚化决定了与β-抑制蛋白的相互作用及其转运模式。
Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1548-53. doi: 10.1073/pnas.0305322101. Epub 2004 Feb 2.
8
An arginyl in the N-terminus of the V1a vasopressin receptor is part of the conformational switch controlling activation by agonist.血管升压素V1a受体N端的一个精氨酰基是控制激动剂激活的构象开关的一部分。
Eur J Biochem. 2003 Dec;270(23):4681-8. doi: 10.1046/j.1432-1033.2003.03865.x.
9
Vasopressin receptors V1a and V2 are not osmosensors.血管加压素受体V1a和V2不是渗透压感受器。
Physiol Rep. 2015 Aug;3(8). doi: 10.14814/phy2.12519.
10
Palmitoylation of the vasopressin V1a receptor reveals different conformational requirements for signaling, agonist-induced receptor phosphorylation, and sequestration.血管加压素V1a受体的棕榈酰化揭示了信号传导、激动剂诱导的受体磷酸化和隔离的不同构象要求。
J Biol Chem. 2001 Oct 12;276(41):38139-46. doi: 10.1074/jbc.M106142200. Epub 2001 Jul 20.

引用本文的文献

1
Pharmacological properties and underlying mechanisms of aurantio‑obtusin (Review).橙皮素的药理特性及潜在机制(综述)
Exp Ther Med. 2023 Jun 26;26(2):380. doi: 10.3892/etm.2023.12079. eCollection 2023 Aug.
2
Understanding Self-Assembly of Silica-Precipitating Peptides to Control Silica Particle Morphology.理解硅沉淀肽的自组装以控制硅粒子形态。
Adv Mater. 2023 Mar;35(11):e2207586. doi: 10.1002/adma.202207586. Epub 2023 Jan 25.
3
Delineating the conformational landscape and intrinsic properties of the angiotensin II type 2 receptor using a computational study.

本文引用的文献

1
Nature-inspired dimerization as a strategy to modulate neuropeptide pharmacology exemplified with vasopressin and oxytocin.受自然启发的二聚化作为一种调节神经肽药理学的策略,以加压素和催产素为例进行说明。
Chem Sci. 2021 Feb 4;12(11):4057-4062. doi: 10.1039/d0sc05501h.
2
Elucidating Solution Structures of Cyclic Peptides Using Molecular Dynamics Simulations.运用分子动力学模拟阐明环肽的溶液结构。
Chem Rev. 2021 Feb 24;121(4):2292-2324. doi: 10.1021/acs.chemrev.0c01087. Epub 2021 Jan 11.
3
Cardiac output improvement by pecavaptan: a novel dual-acting vasopressin V1a/V2 receptor antagonist in experimental heart failure.
通过计算研究描绘血管紧张素II 2型受体的构象景观和内在特性。
Comput Struct Biotechnol J. 2022 May 10;20:2268-2279. doi: 10.1016/j.csbj.2022.05.012. eCollection 2022.
4
Delineating the activation mechanism and conformational landscape of a class B G protein-coupled receptor glucagon receptor.描绘B类G蛋白偶联受体胰高血糖素受体的激活机制和构象变化情况。
Comput Struct Biotechnol J. 2022 Jan 20;20:628-639. doi: 10.1016/j.csbj.2022.01.015. eCollection 2022.
培维索坦改善心输出量:一种新型双重作用血管加压素 V1a/V2 受体拮抗剂在实验性心力衰竭中的作用。
Eur J Heart Fail. 2021 May;23(5):743-750. doi: 10.1002/ejhf.2001. Epub 2020 Oct 9.
4
Luteolin, a Potent Human Monoamine Oxidase-A Inhibitor and Dopamine D and Vasopressin V Receptor Antagonist.木犀草素,一种有效的人单胺氧化酶-A 抑制剂和多巴胺 D 及血管加压素 V 受体拮抗剂。
J Agric Food Chem. 2020 Sep 30;68(39):10719-10729. doi: 10.1021/acs.jafc.0c04502. Epub 2020 Sep 16.
5
The role of oxytocin and vasopressin dysfunction in cognitive impairment and mental disorders.催产素和血管加压素功能障碍在认知障碍和精神障碍中的作用。
Neuropeptides. 2020 Oct;83:102079. doi: 10.1016/j.npep.2020.102079. Epub 2020 Aug 15.
6
Neonatal CSF vasopressin concentration predicts later medical record diagnoses of autism spectrum disorder.新生儿脑脊液血管加压素浓度可预测日后自闭症谱系障碍的医疗记录诊断。
Proc Natl Acad Sci U S A. 2020 May 12;117(19):10609-10613. doi: 10.1073/pnas.1919050117. Epub 2020 Apr 27.
7
Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder.发现巴洛沙肽,一种用于治疗自闭症谱系障碍的血管加压素 1a 受体拮抗剂。
J Med Chem. 2020 Feb 27;63(4):1511-1525. doi: 10.1021/acs.jmedchem.9b01478. Epub 2020 Jan 17.
8
The Ambivalent Role of Proline Residues in an Intrinsically Disordered Protein: From Disorder Promoters to Compaction Facilitators.脯氨酸残基在无规卷曲蛋白质中的双重角色:从促进无序到促进折叠。
J Mol Biol. 2020 Apr 17;432(9):3093-3111. doi: 10.1016/j.jmb.2019.11.015. Epub 2019 Nov 30.
9
Pre- and post-docking sampling of conformational changes using ClustENM and HADDOCK for protein-protein and protein-DNA systems.使用 ClustENM 和 HADDOCK 对蛋白质-蛋白质和蛋白质-DNA 体系进行对接前后构象变化的采样。
Proteins. 2020 Feb;88(2):292-306. doi: 10.1002/prot.25802. Epub 2019 Sep 3.
10
A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder.一项血管加压素 V1a 受体拮抗剂的 2 期临床试验表明,该拮抗剂可改善自闭症谱系障碍男性的适应行为。
Sci Transl Med. 2019 May 8;11(491). doi: 10.1126/scitranslmed.aat7838. Epub 2019 May 1.